$162.78▼-3.06 (-1.84%)
Pre-Market:$162.00-0.78 (-0.48%)· 8:45 PM ET
Neurocrine Biosciences, Inc. (NBIX)
R&D to Revenue
35.51%
Fiscal year · Period ending:

NBIX R&D to Revenue
Latest reported35.51%period ending
Latest reported35.51%period ending
NBIX FY R&D/Revenue (65.63% → 35.51%)
Latest values, visible window
High-resolution chart · PNG
What is r&d to revenue?
R&D spending as percentage of revenue.
NBIX r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 35.5078% | |
| 31.0406% | |
| 29.9401% | |
| 31.1547% | |
| 28.9457% | |
| 26.2931% | |
| 25.3775% | |
| 34.5301% | |
| 56.8145% | |
| 628.6067% | |
| 412.2161% | |
| 0% | |
| 1,344.5701% | |
| 69.9341% | |
| 39.9817% | |
| 92.9853% | |
| 1,141.9573% | |
| 1,397.3333% | |
| 6,698.1209% | |
| 248.9626% | |
| 86.0674% | |
| 135.092% | |
| 127.4616% | |
| 603.7074% | |
| 180.0761% | |
| 275.754% | |
| 173.8095% | |
| 136.25% | |
| 76.2452% | |
| 65.625% |
Explore More
NBIX Financial Metrics
Explore 130+ historical metrics & ratios
Stock Comparison
Compare equities side by side
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Market Movers
Today's biggest gainers and losers
Market Heatmap
Visual sector performance